Refractory multiple myeloma: Count refractory drugs, not lines of treatment!

Area of Science:

• Hematology
• Immunotherapy
• Oncology

Background:

• Current immunotherapeutic agents, such as CAR T-cells, are approved for multiple myeloma patients who have undergone at least 3-4 prior lines of treatment.
• An increasing number of patients are becoming refractory to standard therapies in earlier lines of treatment, limiting their access to potentially life-saving immunotherapies.
• Existing clinical trial inclusion criteria may not adequately reflect the evolving treatment landscape and patient refractoriness patterns in multiple myeloma.

Purpose of the Study:

• To examine the inclusion criteria of ongoing T-cell engaging immunotherapy trials in multiple myeloma.
• To propose a modification of trial criteria to better align with current clinical realities and patient needs.
• To advocate for a shift in focus from the number of prior therapy lines to the degree of treatment refractoriness.

Main Methods:

• Review and analysis of the inclusion criteria for currently enrolling T-cell engaging trials in multiple myeloma.
• Evaluation of the current emphasis on the number of prior lines of therapy in trial eligibility.
• Consideration of refractoriness to a specific number of agents as a potential alternative or supplementary criterion.

Main Results:

• Current T-cell engaging trials in multiple myeloma predominantly use the number of prior lines of therapy as a key eligibility criterion.
• This approach may exclude patients who have become refractory to multiple agents but have not yet received the requisite number of treatment lines.
• The study highlights a potential mismatch between trial designs and the clinical management of refractory multiple myeloma.

Conclusions:

• The current inclusion criteria for multiple myeloma immunotherapy trials should be re-evaluated.
• Future protocols should consider emphasizing refractoriness to 3 or more agents over a strict line-of-therapy count.
• Adjusting these criteria could broaden patient access to innovative immunotherapies, particularly CAR T-cell therapies, for those with earlier treatment failure.